Ask AI
ProCE Banner Series

HER2-Positive Advanced GI Cancers: Expert Guidance on Leveraging Targeted Agents to Improve Outcomes

Join us either in-person or online for this CME-certified symposium held in conjunction with the 2023 ASCO Annual Meeting featuring expert perspectives on testing guidelines and targeted therapies for HER2-positive GI cancers. Bring your questions for the live Q&A session with the expert panel faculty at the end of the session.

To Register: Please click the green “Learn More” button below. On the next page, select either Register for In-Person Event or Register for Virtual Event. Once registered, you will receive a confirmation email. Follow-up emails with event details will be sent as the event nears. 

For more information on ASCO’s Health and Safety policy for this event, please visit ASCO’s website.

Not an official event of the 2023 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, CancerLinQ®, or Conquer Cancer®, the ASCO Foundation.

  AMA
Credits Available

1.5

Who Should Attend

This program is intended for medical oncologists and other healthcare professionals involved in managing patients with GI cancers.

All Events

HER2-Positive Advanced GI Cancers: Expert Guidance on Leveraging Targeted Agents to Improve Outcomes

Past Events

June

03

2023

7:00 PM - 8:30 PM Central Time (CT)

In-personVirtual

Hilton Chicago, 720 South Michigan Avenue, Chicago, Illinois 60605

Topics

HER2-Positive Advanced GI Cancers: Expert Guidance on Leveraging Targeted Agents to Improve Outcomes

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.

CME/CE Info

Goal Statement
This program aims to improve learners’ knowledge, confidence, competence, and performance in evidence-based HER2 testing and the integration of modern HER2-directed therapeutics into treatment algorithms for patients with GI cancers.

Target Audience
This program is intended for medical oncologists and other healthcare professionals involved in managing patients with GI cancers. 

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Integrate guideline-recommended HER2 testing in the management of patients with gastric, colorectal, and other GI cancers
  • Appraise available/emerging safety and efficacy data to appropriately identify patients with HER2-positive GI cancers that would benefit from HER2-targeted therapy
  • Evaluate the importance of biomarker testing results, the latest clinical evidence, current guideline recommendations, and relevant patient-specific, disease-specific, and treatment-specific factors to aid in the development of individualized management plans for patients with HER2-positive GI cancers
  • Implement strategies incorporating the patient and multidisciplinary care team in the effective identification and management of treatment-related adverse events related to novel therapies for HER2-positive GI cancers
  • Identify patients with HER2-positive GI cancers who are candidates for participation in clinical trials

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC.

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Seagen Inc.

For customer support please click here.

Mailing Address:

 

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 304
Reston, VA 20191